05/25 Taiwan BIO Weekly
2026-05-25 |
| Taiwan BIO Weekly |
| Smart health care cooperation critical for Taiwan, Türkiye 22 May, 2026 The convergence of health care and technology has moved beyond simple digitalization into a sophisticated era of artificial intelligence (AI). As both Taiwan and Türkiye prioritize high-tech medical sectors, the integration of AI offers a transformative bridge for bilateral cooperation. By combining Taiwan's data-rich ecosystem and hardware prowess with Türkiye's rapid digital adoption and large-scale hospital initiatives, the two nations can create a "Smart Health Corridor" that safeguards global health security. More... |
| AI-Powered cancer diagnostics make waves at major Taiwan conference 22 May, 2026 A major oncology conference in Taipei became the stage for the formal introduction of next-generation cancer diagnostics to Taiwan's medical community, signaling a potential shift in how the disease is detected and managed. Gene Solutions, a global biotechnology firm, made its inaugural appearance at the 30th Taiwan Joint Cancer Conference (TJCC 2026), showcasing a suite of AI-powered liquid biopsy technologies that drew significant interest from the nation's top oncologists. More... |
| Formosa Pharmaceuticals Announces Presentation of TSY-310 at the 2026 ASCO Annual Meeting Press release 21 May, 2026 Formosa Pharmaceuticals, Inc. (TW: 6838) announces that its abstract highlighting the differentiated binding profile and preclinical efficacy of TSY-310, a novel bispecific antibody-drug conjugate (ADC), has been selected for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29-June 2, 2026, in Chicago, Illinois. TSY-310 simultaneously targets EGFR and ROR1, two receptors frequently co-expressed in prevalent solid tumors. By leveraging a unique bispecific modality, TSY-310 optimizes target engagement and intracellular delivery, facilitating a potent bystander effect to address the challenges of tumor heterogeneity. More... |
| Bonraybio optimistic on growing demand for assisted reproduction 21 May, 2026 Bonraybio (TW: 6955) said rising global infertility rates and growing demand for assisted reproduction are expected to support steady business growth, as the company continues expanding the applications and market reach of its AI-powered sperm testing products. The company's smart diagnostic devices can deliver reproductive health data in as little as one minute, helping fertility centers and medical institutions improve testing efficiency and accuracy. More... (in Chinese) |
| Lotus Pharmaceuticals to acquire Swiss-headquartered OM Pharma's S. Korea-based specialty UTI drug 21 May, 2026 Lotus Pharmaceuticals (TW: 1795) announced it has signed an agreement with Geneva-based biopharma company OM Pharma to acquire its South Korea-based specialty drug for preventing recurrent urinary tract infections, including related licenses, trademarks, inventory, and intellectual property. The product, already sold in over 40 countries and used by more than one million patients, is expected to strengthen Lotus Pharmaceuticals' specialty portfolio and expand its footprint in South Korea, a key Asian market. More... (in Chinese) |
| AI drug discovery engine launches: GGA and AMS BioteQ target pancreatic cancer and dengue fever 20 May, 2026 Genetics Generation Advancement (TW: 4160) has partnered with Dr. Hu Chun-Mei's team at Academia Sinica and Anti-Microbial Savior BioteQ (TW: 6864) to advance AI-driven drug discovery using its partner French software giant Dassault Systèmes' platform, targeting pancreatic cancer and dengue fever. The collaboration has shortened pancreatic cancer drug candidate development from two to three years to about three months, while also pursuing a broad-spectrum oral dengue treatment effective against all four DENV serotypes, addressing a major unmet global medical need. More... |
| AI Startups in Taiwan's Healthcare Testbed 20 May, 2026 Artificial intelligence is often discussed in sweeping terms -- productivity, transformation, disruption -- but many of Taiwan's healthcare startups are approaching the technology from a more targeted direction. Rather than building generalized AI, they are applying machine learning, data analysis, and real-time diagnostic and tracking tools to address clinical bottlenecks and introduce patients to both routine and life-saving tools. More... |
| AetherAI debuts on Taiwan Innovation Board as digital pathology demand grows 20 May, 2026 AetherAI Co. (TW: 7803), a biotechnology company focused on digital pathology and artificial intelligence-based medical solutions, debuted on the Taiwan Innovation Board on Wednesday. More... |
| Taiwan stages smart medical tech expo in Geneva 19 May, 2026 The Taiwan Smart Medical and HealthTech Expo got underway May 17 in Geneva to spotlight the country's critical role in promoting global health resilience. Commissioned by the Ministry of Foreign Affairs and organized by Taipei City-based Taiwan External Trade Development Council, the three-day event is being held on the sidelines of the 79th World Health Assembly taking place May 18-23 in the Swiss city. More... |
| MegaPro Biomedical's RegenTrace wins top international award, plans to enter critical limb ischemia market 19 May, 2026 MegaPro Biomedical (TW: 6827) said its nanoparticle platform-based cell therapy candidate MPB-2354 (RegenTrace) won top prize at an international innovation competition, prompting the company to accelerate its US expansion strategy. The board has approved the establishment of a US subsidiary and the launch of a US$10 million Series A fundraising round to support planned Phase I/IIa clinical trials in the United States beginning next year, as the company targets the lucrative US critical limb ischemia (CLI) market. More... (in Chinese) |
| Locus Cell launches Zhubei smart factory to scale up cell therapy manufacturing 19 May, 2026 One-shot cell therapies that cost over NT$1 million per dose have long faced challenges in scalability and cost reduction due to heavy reliance on manual manufacturing processes. Taiwan regenerative medicine company Locus Cell (TW: 6891) has officially launched its smart cell therapy factory located in the Zhubei Biomedical Park in Hsinchu, introducing AI, automation, and robotics into its production workflow in an effort to move cell therapies from a lab-scale model toward true large-scale manufacturing. The facility, which took 2.5 years to complete and represents an investment of over NT$1 billion, spans 10 floors and is positioned as one of the few manufacturing bases in Asia purpose-built for cell therapy production. More... (in Chinese) |
| Bora Pharmaceuticals lands NT$10B CDMO deal with 10-year term 18 May, 2026 Bora Pharmaceuticals (TW: 6472) announced on the 18th of May that it has signed a major manufacturing agreement worth more than NT$10 billion with an undisclosed top-20 multinational pharmaceutical company. The contract carries an initial term of 10 years with a two-year extension option. Through Bora Pharmaceuticals' global manufacturing network, the two parties will provide one-stop support spanning development, manufacturing, packaging, and analytical services. The client is expected to become one of Bora Pharmaceuticals’ top three CDMO (contract development and manufacturing organization) customers. More... (in Chinese) |
| Taiwan Bio Therapeutics partners with world-leading Mayo Clinic 17 May, 2026 Taiwan Bio Therapeutics (TW: 6892) announced on the 17th of May that its board has approved a technology licensing and equity investment agreement between its US subsidiary Singulera Therapeutics and the world's top-ranked medical center, Mayo Clinic, for next-generation CAR-Treg (chimeric antigen receptor regulatory T-cell) technology. Through the deal, Mayo Clinic will become an important strategic shareholder in Taiwan Bio Therapeutics by contributing technology as equity. Under the preliminary agreement, Singulera Therapeutics will obtain exclusive global development and commercialization rights to the next-generation CAR-Treg technology from Mayo Clinic, while providing an 8% equity stake as the upfront licensing fee. More... (in Chinese) |
| ========================================= |
| Taiwan Bio Industry Organization (Taiwan BIO) Tel: +886 2 27836028 Fax: +886 2 27836027 Email: biotaiwan@gmail.com BIO Asia-Taiwan 2026 (15-19 July, 2026) ========================================= Taiwan Bio Industry Organization (Taiwan BIO) Room C229, 2F, Bldg. C, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei, Taiwan (11571) ========================================= |